Navigation Links
EntreMed Reports Clinical Program Progress and Company Update
Date:11/12/2008

ROCKVILLE, Md., Nov. 12, /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, reported corporate and clinical program updates for the third quarter 2008 and remaining fourth quarter 2008 objectives. The updates were given during a podium presentation by EntreMed President & CEO, James S. Burns, and web cast at the Rodman & Renshaw 10th Annual Healthcare Conference, being held this week in New York. An archive of Mr. Burns' live presentation is available on the Company's web site at http://www.entremed.com and can be accessed for 60 days.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

During the presentation, Mr. Burns reiterated the development status of the Company's pipeline of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. Remarks during the presentation were focused on corporate objectives as they relate to the status of multiple oncology clinical trials currently underway, the Company's partnering goals, and financial position. Highlights of the presentation are listed below.

Corporate Highlights

-- EntreMed, Inc. reported third quarter royalty revenues of approximately

$3.5 million from sales of Thalomid(R). Royalty revenues for the full

year 2008 are expected to increase over 2007 based on additional sales

of Thalomid(R) resulting from Celgene's acquisition of Pharmion.

-- EntreMed, Inc. ended the third quarter 2008 with approximately $28

million
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Human guinea pigs wary of high-paying medical trials 2
... care visits to family doctors are declining, rese...Day News) -- Specialists are increasingly providin...ionally been handled by primary care doctors, a ne... visits for specialized care is for routine and pr...
... Workman proudly touts support of Sam Schmidt Para... While Punch Energy Drink,s well-recognized tagli...orkman, Punch Energy Founder and 21-year-old bever...oday, Workman proudly announced that the Sam Schmi...
...leadership needed to manage growth , , WAYNE, Pa....f clinical documentation software, workflow tools ...and realigning its organization by service and sol...ion Services and James Stewart, Vice President of ...
..., March 10 More physician leaders are embracing t...records, but most still consider them clunky and u...ults found in a recent survey by the American Coll... management. , , ACPE conducted the same survey b...
... March 10 LCA-Vision Inc. (Nasdaq: LCAV ) today...arison of excimer laser platform technologies, the...of platforms at each of its Lasik Plus (R) vision ...ly no later than the end of the third quarter of 2...
...arch 10, 2009 Forest Laboratories, Inc. (NYSE: ...rma GmbH & Co. KGaA, and Merz Pharmaceuticals ...emark Office has issued a Notice of Final Determin... Administration Orange Book for NAMENDA(R) (memant...
Other Medicine News:Health News:For Primary Care, More Patients Are Seeing Specialists 2Health News:For Primary Care, More Patients Are Seeing Specialists 3Health News:Punch Energy Drink Announces Recipient of Its Inaugural LIVE BETTER AWARD(R) 2Health News:Punch Energy Drink Announces Recipient of Its Inaugural LIVE BETTER AWARD(R) 3Health News:Precyse Solutions Adds Executives, Realigns Around Service Lines 2Health News:Survey Results: Health Care Technology Advances as Physician Frustration Grows 2Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 2Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 3Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 4Health News:USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA(R) 2
(Date:12/3/2009)MADISON, N.J., Dec. 3 A genetic variation that may indicate a patient,s risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is
(Date:12/3/2009)DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunitie
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
Breaking Medicine Technology:Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Echo Therapeutics Announces Significant Advance in Development of its One Piece Needle Free Symphony tCGM Biosensor 5825 1Echo Therapeutics Announces Significant Advance in Development of its One Piece Needle Free Symphony tCGM Biosensor 5825 2Echo Therapeutics Announces Significant Advance in Development of its One Piece Needle Free Symphony tCGM Biosensor 5825 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 1Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 2Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 4Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 5Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 6Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 7Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 8Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 9Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 10Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 11Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 12Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 13Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 14Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 15Dr Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics 5815 1Dr Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics 5815 2Dr Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics 5815 3
...S, Oct. 26 The complex cases performed,during thi... Therapeutics,symposium by Dr. Tony Das, an interv...Dallas, represent the latest treatments for periph... the U.S. population ages and more,Americans live ... will also,dramatically increase the number of peo...
...SLEY, Mass., Oct. 26 Coley,Pharmaceutical Group, ...mpany,has received a $3.0 million milestone paymen...nitiation of GSK,s Phase III clinical trial in,non...eutic cancer vaccine,containing Coley,s VaxImmune(... the launch of the largest Phase III,clinical tria...
Other Medicine Technology:Cardiologists Tackle 'Next Frontier' in Cardiovascular Disease 2Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 2Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 3
High Lite Convertible
High Lite Classic
High Beam Classic
...nalyzer is a semi-automated benchtop instrument fo...nQuick is designed to analyze and generate results...k 8+ urine test strips. The UrinQuick analyzes the...y. Test results are available in conventional, S.I...
Medicine Products: